Russia

According to the FDA Report, Russia placed in the top 10 and ranked 2nd after the U.S. in terms of the number of subjects recruited. Russia is the world's 9th country by population (146 mln people), making it a patient pool more than sufficient for a study in almost any indication.

Czech Republic

The leading therapeutic areas in terms of the approvals in 2021 were Oncology, Neurology, Cardiology, Rheumatology. Besides, the country offers competitive advantages for trials in niche areas such as rare and orphan diseases, stem cell and gene therapies.

Hungary

Clinical trials in Hungary are in high demand, as the region is a unique combination of all the important aspects: fast enrollment, low prices, and a remarkable level of quality. Out 50 novel drugs approved by the FDA in 2021, 14 have undergone studies at Hungarian sites.

Spain

Today 145,000 patients are involved in 3,400 clinical trials in progress in Spain. While one out of three trials carried out in Europe already has Spanish participation, the country accounts for a 4.3% share of the global clinical trials activity with oncology as the leading therapeutic area.

Bulgaria

In 2014-2019 Bulgaria was placed in the top 10 and ranked 8th in terms of the number of subjects recruited for studies according to the recent US FDA Report. 13 out of 50 novel drugs approved by the FDA in 2021 underwent studies in Bulgaria.

Romania

Romania has been drawing a lot of interest for international Sponsors. The 12th largest state in Europe offers speedy start-up, specialized healthcare services, experienced personnel with advanced knowledge of eClinical solutions, and record recruitment rates across various therapeutic areas.

Poland

Poland is 10th place in the world by number of research sites (over 1,400). With a population of 38.5 mln people, it boasts successful recruitment rates, reasonable grants, and lower costs per patient than in the U.S., though higher than in Ukraine, Russia or Georgia.

Latvia

Being an EU member since 2004, Latvia boasts a harmonized regulatory and legislative environment for international clinical trials. The majority of studies fall within the therapeutic areas of oncology, neurology, psychiatry, and endocrinology.

Belarus

Belarus is a promising new player. Clinical research professionals are very particular about adhering to GCP standards. Local rules and standards are very close to those mandated by FDA and EMA.

Ukraine

Recruitment shows a significant number of eligible patients, including treatment-naïve ones. According to the MoH of Ukraine, leading therapeutic areas in 2020 are Oncology, Psychiatry, Neurology, Gastroenterology, and Hematology. The RA process takes up to 60 calendar days.

Delivering high-quality CRO services
since 2005

Experience the benefits of running your next study in Eastern Europe

Contact our regional office

Operations in 18 countries:

Latvia
Poland
Romania
Hungary
Czech Republic
Spain
Ukraine
Bulgaria
the Netherlands
Georgia
Estonia
Lithuania
Belarus
Serbia
Russia
Kazakhstan
Croatia
Moldova

More Countries

An official member of the European CRO Federation

How we reached 100% recruitment 7 months ahead of schedule for Samsung Bioepis lung cancer study

Free Feasibility Report Send a request

How we reached 100% recruitment 7 months ahead of schedule for Samsung Bioepis lung cancer study

Free Feasibility Report Send a request

up to

faster enrollment

access to

2,100

leading research sites

we have enrolled

58,937

patients up to date

we deliver

EMA/FDA

acceptable data

Tailored approach to every project ●

1.5 x faster enrollment rate for any area ●

An email or a phone call away ●

Full Range of Clinical Trial Services

Clinical Study Design Preparation

Medical Writing

Consulting and Regulatory Support

Drug Safety and Pharmacovigilance

Project Management and Monitoring

Clinical Data Management

Biostatistics

Clinical Supply Services and Logistics

The study has been going on during challenging times, and I am proud of our joint recruitment efforts with OCT Clinical. Without their resilience, energy, amazing control, efficiency and cooperative approach we wouldn’t have got here so soon.

Andreas Gerward
CEO, Stayble Therapeutics

We are happy that we came across OCT Clinical to run the next phase of our clinical study, We have been impressed with the CRO’s portfolio and are counting on their professionalism and performance.

Yong Liu
CEO, Recbio

300+ Studies in 29 Therapeutic Areas
Since 2005

OCT Clinical to the Rescue

Rescue Studies as a Special Expertise

When clinical trials hit roadblocks, we are ready to step in. Each time we takeover an active trial, our experts create a study rescue plan focused on resolving current bottlenecks and study challenges and an expedited study schedule to get it back on track.

Request a Proposal